DJIA 16,251.14 192.79 1.20%
NASDAQ 4,700.68 64.58 1.39%
S&P 500 1,934.29 20.44 1.07%
market minute promo

Isis Pharmaceuticals (NASDAQ: ISIS)

50.75 2.00 (4.10%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

ISIS $50.75 4.10%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $49.05
Previous Close $48.75
Daily Range $48.65 - $50.91
52-Week Range $35.26 - $77.80
Market Cap $6.1B
P/E Ratio 256.58
Dividend (Yield) $0.00 (0.0%)
Volume 979,292
Average Daily Volume 1,750,931
Current FY EPS -$0.52

Sector

Healthcare

Industry

Drug Makers

Isis Pharmaceuticals (ISIS) Description

The Company is a biopharmaceutical company exploiting proprietary RNA-based drug discovery technologies to create a new class of drugs to treat important diseases. Website: http://www.isispharm.com/

News & Commentary

Isis' News-Filled Week

The biotech announces a new partnership, clinical trial results, and earnings over the course of two days.

5 Top BioPharma Stocks That May Have Sold Off Too Much and Become Bargains

3 Promising Biotechs Hobbled By First-Impression Issues

Isis Pharmaceuticals Enters Oversold Territory (ISIS)

Isis Pharmaceuticals Misses on Q2 Earnings and Revenues - Analyst Blog

Isis Pharmaceuticals Misses on Q2 Earnings and Revenues - Analyst Blog

Isis Pharmaceuticals (ISIS) Earnings Report: Q2 2015 Conference Call Transcript

Isis Pharmaceuticals' (ISIS) CEO Stan Crooke on Q2 2015 Results - Earnings Call Transcript

Isis Pharmaceuticals (ISIS) Misses Earnings Estimates in Q2 - Tale of the Tape

Will Isis Pharmaceuticals (ISIS) Beat Q2 Earnings Estimates? - Analyst Blog

Isis Pharma 8-K Filing Shows Company Enters Agreement with Astrazeneca To Discover And Develop Antis

Isis Pharma 8-K Filing Shows Company Enters Agreement with Astrazeneca To Discover And Develop Antisense Drugs FOr Cardiovascular, Metabolic And Renal Disease

See More ISIS News...

ISIS's Top Competitors

ISIS $50.75 (4.10%)
Current stock: ISIS
AMGN $149.10 (1.11%)
Current stock: AMGN
GILD $102.94 (1.43%)
Current stock: GILD
BIIB $302.19 (3.31%)
Current stock: BIIB